Article Dans Une Revue Oncogene Année : 2024

Recent insights into the therapeutic strategies targeting the pseudokinase PTK7 in cancer

Charlotte Dessaux
  • Fonction : Auteur
Laetitia Ganier
  • Fonction : Auteur
Louis Guiraud
  • Fonction : Auteur

Résumé

The generation of drugs counteracting deregulated protein kinases has been a major focus in cancer therapy development. Breakthroughs in this effort have produced many therapeutic agents to the benefit of patients, mostly through the development of chemical or antibody-based drugs targeting active kinases. These strategies are challenged when considering catalytically inactive protein kinases (or pseudokinases), which represent 10% of the human kinome with many of relevance in cancer. Among the so-called pseudotyrosine kinases, the PTK7 receptor tyrosine kinase (RTK) stands as a bona fide target overexpressed in several solid tumors and hematological malignancies and linked to metastasis, poor prognosis, and resistance to treatment. Despite the lack of catalytic activity, PTK7 has signaling capacities through heterodimerization with active RTKs and offers pharmacological targeting opportunities through its inactive kinase domain. Moreover, PTK7-targeting strategies based on antibody-drug conjugates, aptamers, and CAR-T cell-based therapies have demonstrated encouraging results in preclinical and clinical settings. We review the most recent data assigning to PTK7 a prominent role in cancer progression as well as current preclinical and clinical targeting strategies against RTK family pseudokinases including PTK7.

Fichier principal
Vignette du fichier
Dessaux C et al, Oncogene, 2024.pdf (1.99 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

hal-04946041 , version 1 (13-02-2025)

Licence

Identifiants

Citer

Charlotte Dessaux, Laetitia Ganier, Louis Guiraud, Jean-Paul Borg. Recent insights into the therapeutic strategies targeting the pseudokinase PTK7 in cancer. Oncogene, 2024, 43 (26), pp.1973-1984. ⟨10.1038/s41388-024-03060-x⟩. ⟨hal-04946041⟩
71 Consultations
127 Téléchargements

Altmetric

Partager

  • More